Getting the Deal Through: Pharmaceutical Antitrust 2020
Getting the Deal Through: Pharmaceutical Antitrust 2020

The following In-house Advisor practice note provides comprehensive and up to date legal information covering:

  • Getting the Deal Through: Pharmaceutical Antitrust 2020
  • Jurisdictions covered
  • Questions

Jurisdictions covered

The following jurisdictions are covered in this report:

Brazil; Bulgaria; Canada; China; European Union; Finland; France; Germany; India; Japan; Norway; Portugal; Romania; Spain; Turkey; United Kingdom; USA


The set of questions relating to the topic of Pharmaceutical Antitrust and answered by the guide for each jurisdiction covered include:

  1. What is the applicable regulatory framework for the authorisation, pricing and marketing of pharmaceutical products, including generic drugs?

  2. Which authorities are entrusted with enforcing these rules?

  3. Are drug prices subject to regulatory control?

  4. Is the distribution of pharmaceutical products subject to a specific framework or legislation? Do the rules differ depending on the distribution channel?

  5. Which aspects of the regulatory framework are most directly relevant to the application of competition law to the pharmaceutical sector?

  6. What are the main competition law provisions and which authorities are responsible for enforcing them?

  7. What actions can competition authorities take to tackle anticompetitive conduct or agreements in the pharmaceutical sector and what remedies can they impose?

  8. Can remedies be sought through private enforcement by a party that claims to have suffered harm from anticompetitive conduct or agreements implemented by pharmaceutical companies? What form would such remedies typically take and how can they be obtained?

  9. Can the antitrust authority conduct sector-wide

Related documents:

Popular documents